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We have previously observed the spontaneous, pH-dependent
insertion of a water-soluble peptide to form a helix across lipid
bilayers [Hunt, J. F., Rath, P., Rothschild, K. J. & Engelman, D. M.
(1997) Biochemistry 36, 15177–15192]. We now use a related
peptide, pH (low) insertion peptide, to translocate cargo molecules
attached to its C terminus across the plasma membranes of living
cells. Translocation is selective for low pH, and various types of
cargo molecules attached by disulfides can be released by reduc-
tion in the cytoplasm, including peptide nucleic acids, a cyclic
peptide (phalloidin), and organic compounds. Because a high
extracellular acidity is characteristic of a variety of pathological
conditions (such as tumors, infarcts, stroke-afflicted tissue, athero-
sclerotic lesions, sites of inflammation or infection, or damaged
tissue resulting from trauma) or might be created artificially, pH
(low) insertion peptide may prove a useful tool for selective
delivery of agents for drug therapy, diagnostic imaging, genetic
control, or cell regulation.
drug delivery  peptide nucleic acid delivery  tumors  membrane
transport  helix formation
We suggest that spontaneous insertion and formation oftransbilayer -helices can be used as an approach to
moving chemical reagents through the permeability barrier of
biological membranes. Membrane proteins, which represent
30% of all ORFs in sequenced genomes (1, 2), play a key role
in many fundamental cellular processes, such as signal and
energy transduction, active transport, ion flow, cell–cell inter-
actions, and nerve conduction. Based on the two-stage model of
helical membrane protein folding, the formation of indepen-
dently stable helices across the membrane lipid bilayer occurs
first, and then the interaction of the helices with each other leads
to the stabilization of higher-order structure (3, 4). Folding and
insertion of large-membrane protein domains into targeted
membranes require active participation of complex translocation
machineries (5–7), whereas insertion of short (50- to 60-
residue) protein sequences can occur spontaneously (8–10). In
recent work, some cases of apparent spontaneous insertion have
been shown to require a membrane protein, YidC (11). We
previously reported that a polypeptide derived from the bacte-
riorhodopsin C helix, consisting of the transmembrane sequence
and two flanking sequences, is soluble in aqueous solution and
spontaneously inserts across lipid bilayers in a pH-dependent
manner (12, 13), with no requirement for additional proteins
such as YidC. Here we report that a related peptide, pH (low)
insertion peptide (pHLIP), which inserts across a cell membrane
at low pH (7.0), can translocate a drug or imaging molecule
into the cell and release it in the cytoplasm (Fig. 1a).
Results
At neutral pH, a polypeptide derived from the bacteriorhodop-
sin C helix binds weakly to the surface of a liposome, whereas at
acidic pH (7.0) it inserts across a membrane and forms a
transmembrane -helix (12, 13). Our strategy is to conjugate a
cargo molecule by means of a disulfide bond to the end of the
transmembrane peptide that inserts into the cell, where the
reducing environment of the cytoplasm will break the disulfide
and release the cargo. Our first task was to identify the topology
of the insertion of the peptide. We used the membrane-
impermeable dithionite ion (S2O42), which can chemically
modify the 4-chloro-7-nitrobenz-2-oxa-1,3 diazole (NBD) flu-
orophore and quench its f luorescence (14), to probe a label
placed at one end of the peptide. The peptide, labeled with NBD
at its N terminus, was inserted into 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) liposomes, which led to a
shift of the maximum position of the NBD fluorescence spec-
trum from 555 (in the absence of liposomes) to 530 nm. The
maximum position of the NBD fluorescence at 530 nm indicates
that the fluorophore is located in an environment with a
dielectric constant of70 (15) on the border between water and
membrane. Addition of the dithionite ion to the solution of
peptide inserted into POPC led to the complete quenching of
NBD fluorescence (Fig. 1b). We also prepared liposomes with
dithionite trapped inside them. These liposomes were added to
the labeled peptide at neutral pH, and then the pH was lowered
to trigger peptide insertion. No change in fluorescence signal was
seen (Fig. 1c), showing that dithionite trapped in the liposomes
did not react with NBD, that there is no leakage of dithionite,
and that the N terminus of the peptide is located outside of the
liposome. Disruption of the liposomes by Triton X-100 led to the
release of dithionite ions and the quenching of NBD fluores-
cence. Because we know that the peptide forms a transmem-
brane helix (12) and NBD labeling usually does not affect the
process of protein or peptide insertion into lipid bilayers (16), we
assume that the N terminus stays outside, whereas the C
terminus of the peptide is translocated across the bilayer, which
is the natural topology of the C-helix in bacteriorhodopsin. Our
subsequent experiments (below) are consistent with this topol-
ogy. We decided to use two strategies: to label the cell surface
by attaching molecules to the N terminus or to insert molecules
inside cells by attaching them to the C terminus.
To evaluate the ability of the peptide to translocate molecules
through a cell membrane, we synthesized a version of the peptide
(pHLIP) with a single cysteine residue at its C terminus (AAE-
QNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG),
allowing it to be easily conjugated to a variety of molecules either
via a disulfide bond, which should be cleaved in the reducing
environment of the cytoplasm, or via a noncleavable covalent
bond. To study pH-dependent translocation of molecules
through the cell membrane, we first prepared pHLIP conjugated
via a disulfide bond to dansyl dye (see chemical structure in Fig.
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7a, which is published as supporting information on the PNAS
web site) and tested the construct with live HeLa cells at
different pHs (Fig. 2a). Our protocol was to add the fluores-
cently labeled peptide to cells and incubate for 15 min at pH 5.5,
6.5, 7.0, or 7.4 and then to wash the cells at pH 7.4 to remove any
reversibly bound peptide. The uptake of dansyl was significantly
higher at low pH (Fig. 2b). The relative uptakes were 18%, 48%,
78%, and 100% at pH 7.4, 7.0, 6.5, and 5.5, respectively.
Because it is among the most useful functional cargo-
molecules, we studied the translocation of peptide nucleic acid
(PNA). Studies in vitro indicate that PNA can inhibit both
transcription and translation of genes to which it has been
targeted, which holds promise for its use for antigene and
antisense therapy (17–19). However, the major obstacle is the
delivery of PNA [as well as RNA or oligonucleotide (ODN)]
across the membrane into a cell. We examined the ability of
pHLIP to translocate a fluorescent-labeled 12-base PNA (see
sequence of PNA in Fig. 7b) into the cells. Cells were incubated
with pHLIP–S–S-PNA–carboxytetramethylrhodamine
(TAMRA) and subsequently washed to remove reversibly bound
peptide. No retention of fluorescence was seen in the cells at
normal pH, but significant cytoplasmic fluorescent staining of
cells was observed at low pH (Fig. 3a). The treatment of cells
with PNA–TAMRA did not show fluorescent staining of cells at
pH 6.5 or 7.4. We verified that the labeled cells were alive by
using the dead cell marker SYTOX–Green. Fig. 3b shows the
cells labeled with PNA–TAMRA translocated by pHLIP at pH
6.5 (Left) and the same cells treated with SYTOX–Green (Right).
The majority of cells have only PNA–TAMRA, whereas only a
few cells had both PNA–TAMRA and SYTOX–Green. We also
tried to translocate a 20-base ODN; however, no uptake of a
pHLIP–S–S–ODN–FITC (see sequence of ODN in Fig. 7c)
construct at normal or low pH was seen (data not shown). The
fact that pHLIP was unable to translocate ODN at any pH but
can translocate other cargo molecules selectively at low pH
argues against the involvement of endocytosis, as do the other
data (see below). We conclude that relatively uncharged mole-
cules such as PNAs can be translocated but that highly charged
nucleic acids cannot.
We studied delivery of a cyclic peptide cargo using a toxin
from the deadly Amanita phalloides mushroom, phalloidin (see
chemical structure of phalloidin in Fig. 7d). Phalloidin is a
water-soluble, cell-impermeable bicyclic peptide. If it enters a
cell, it binds tightly to actin filaments at nanomolar concentra-
tion and strongly inhibits their depolymerization (20, 21). Flu-
orescent phalloidin is commonly used as a specific marker of
actin filaments in permeabilized cells. Actin filaments stained
with fluorescent phalloidin have an unmistakable filamentous
pattern, distinct from the appearance of other cellular structures,
organelles, or membrane staining. Therefore, the delivery of
fluorescent phalloidin by our construct into live cells provides
morphological evidence of the proposed molecular translocation
mechanism. The biological effects of translocation of phalloidin
into live cells should be an inhibition of cell contractility and
division. In particular, we expect that attached cells would not
contract and round up in response to EDTAtrypsin treatment.
A long-term effect of phalloidin could be the formation of
multinucleated cells, because nuclei might divide but treated
cells cannot. Each of these expectations has been confirmed
experimentally (see below).
We conjugated a bifunctional, photoactivatable crosslinker via
an S–S bond to the C terminus of pHLIP and coupled it to
f luorescently labeled phalloidin [phalloidin–tetramethylrho-
damine B isothiocyanate (Ph–TRITC)] by photoactivation. We
observed staining of actin filaments of cells incubated with
pHLIP–S–S–Ph–TRITC at low pH but not at normal pH (Fig.
4a). The treatment of cells with Ph–TRITC or crosslinker–Ph–
TRITC in the presence or absence of peptide did not give
fluorescent staining of actin filaments at any pH studied. We
Fig. 1. pHLIP insertion and topology. (a) Schematic diagram of cargo mol-
ecule delivery into a cell. At physiological pH, the peptide–cargo conjugate
interacts weakly with a membrane. At low pH, the peptide forms a transmem-
brane helix with its C terminus inserted in the cytoplasm. Reduction of the
disulfide bond releases a drug. (b) The topology of the pHLIP peptide in a lipid
bilayer was determined by using the NBD–dithionite quenching reaction. The
fluorescence signal of NBD attached to the N terminus of peptide was mon-
itored at 530 nm when excited at 470 nm. Sodium dithionite was added to the
NBD peptide inserted into POPC large unilamellar vesicles. (c) POPC large
unilamellar vesicles containing dithionite ion inside were added to the NBD
peptide at pH 8.0, and then decreasing the pH triggered insertion of the
peptide in liposomes. Triton X-100 was used for the disruption of liposomes.
The concentration of the peptide used in the experiments was 7 M.
Fig. 2. pHLIP transport of dansyl into cells. (a) Fluorescence images of HeLa
cells incubated (for 15 min) with cleavable pHLIP–S–S–dansyl construct (7 M)
at pH 5.5, 6.5, 7.0, and 7.4 and washed with PBS buffer at pH 7.4 are shown.
(b) Quantification of fluorescence images. The fluorescence signal of cells at
pH 5.5 was taken as 100%. The uptake of dansyl strongly decreases with an
increase of extracellular incubation pH.

















tested delivery in human (HeLa) andmouse (prostate, TRAMP-
C1; breast, JC) cancer cell lines. In each case, we observed the
characteristic staining of actin filaments in the target cells at
pH  7.0 (Fig. 4b).
To demonstrate that pHLIP itself does not enter the cell, we
exploited the fact (reported in ref. 11) that a pH increase leads
to the reversal of insertion and the release of the peptide from
lipid bilayers. We conjugated Ph–TRITC to the C terminus of
the peptide via a noncleavable covalent bond incubated with
cells at pH 6.5 and washed with buffer at the same pH. As
expected, we observed fluorescence mostly from the plasma
membranes; however, when cells were washed with the buffer at
pH 7.4, the pHLIP–Ph–TRITC constructs were removed, and
only traces of residual f luorescence were seen (Fig. 8a, which is
published as supporting information on the PNAS web site).
These procedures were repeated with the peptide conjugated to
Texas red and rhodamine (data not shown), with similar results.
These experiments demonstrate that cells do not internalize the
peptide with covalently attached cargo and argues against any
involvement of endocytosis or receptor-mediated uptake.
We investigated pHLIP’s cytotoxicity and its ability to induce
membrane leakage. The incubation of HeLa cells with peptide
at concentrations up to 16 M for 24 h under physiological
conditions does not affect cell viability (Fig. 9a, which is pub-
lished as supporting information on the PNAS web site). Mem-
brane leakage was tested by incubation of HeLa cells at various
concentrations of peptide (up to 10 M) at pH 7.4 and 6.5
together with cell-impermeable agents: Ph–TRITC and nuclear-
staining SYTOX–Orange. Then, cells were washed and fluores-
cence was measured (Fig. 9b). The fluorescence values obtained
in absence or presence of various concentrations of pHLIP were
all about the same and 10% of those obtained after cell
membrane disruption by Triton X-100. The data indicated that
pHLIP did not induce the uptake of free Ph–TRITC or SYTOX–
Orange, establishing that the cells are viable and that the
phalloidin uptake depends on linkage to the pHLIP.
We used FACS of HeLa cells in suspension to improve the
quantification of the pH-dependent translocation of fluorescent
phalloidin by pHLIP through the membranes (Fig. 5). Cells
treated with pHLIP–S–S–Ph–TRITC exhibited a very low level
of f luorescence because of limited membrane attachment at pH
7.4. However, at low pH, a population of highly fluorescent cells
was observed. The efficiency of Ph–TRITC delivery into cells at
low temperature was the same as at 37°C. The appearance of
discrete populations of fluorescent cells might reflect a differ-
ence in the delivery of Ph–TRITC to cells in different phases of
the cell cycle. It seems unlikely that the insertion of pHLIP–
Ph–TRITC would depend on the cell cycle, so the difference
might arise from a variation in the rate of reduction of the
disulfide bonds andor the variation of the surface area of cell
membrane. If phalloidin were not released during the incubation
time, it would be removed together with the peptide during cell
washing at pH 7.4, because the insertion of peptide is reversible.
The release of Ph–TRITC inside the cell might depend on the
glutathione concentration, which is known to vary significantly
during the cell cycle, reaching a maximum at G2M and a
minimum at G1 (22). Because the incubation time (1 h) is much
less than the HeLa cell cycle time (18 h), the cells that happen
to be in G2Mmight be expected to take upmore phalloidin than
the rest. On the other hand, the surface area of cells in G2M
phase increases by almost a factor of two, which might lead to
double the number of inserted peptides. Indeed, we observed
that bigger cells (cell size can be estimated from forward light
scattering intensity) emitted more light.
The translocation of phalloidin into cells led to inhibition of
cytoskeleton dynamics and consequent loss of the ability of cells
to contract and round up in response to treatment by EDTA
trypsin dissociation solution (Fig. 6a and Fig. 10, which is
published as supporting information on the PNAS web site).
However, untreated cells (data not shown) or cells treated with
the construct at normal pH were able to round up and dissociate
Fig. 3. The delivery of PNA into cells by pHLIP. (a) Fluorescence and phase-
contrast images of HeLa cells incubated (for 30 min) with a pHLIP–S–S–PNA–
TAMRA cleavable construct (1 M) at pH 7.4 (Left) and 6.5 (Right) are shown.
No translocation was observed of pHLIP–S–S–PNA–TAMRA at pH 7.4 or PNA–
TAMRA at pH 7.4 or 6.5 (data not shown). (b) HeLa cells labeled with PNA–
TAMRA translocated by pHLIP at pH 6.5 (Left) and the same cells treated with
SYTOX–Green (Right). The majority of cells have only PNA–TAMRA, whereas
only one cell had both PNA–TAMRA and SYTOX–Green.
Fig. 4. The delivery of phalloidin into cells by pHLIP. (a) Fluorescence images
of HeLa cells incubated (for 1 h) with a pHLIP–S–S–Ph–TRITC cleavable con-
struct (2 M) at pH 7.4 (Left) and 6.5 (Right) are shown. The fluorescence was
extremely weak after pH 7.4 incubation and localized to the plasma mem-
brane. Strong fluorescence of actin filaments was observed after pH 6.5
incubation. (b) Images of HeLa (Left), breast JC (Center), and prostate
TRAMP-C1 (Right) cancer cells with fluorescent actin filaments are shown.
Cells were incubated for 1 h with the cleavable pHLIP–S–S–Ph–TRITC (0.5–1
M) at pH 6.5 followed by washing with PBS at pH 7.4.
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from the surface. We observed formation of multinucleate cells
after 48 h of treatment with pHLIP–S–S–Ph–TRITC (Fig. 6b).
The appearance of multinucleated cells has been also reported
after treatment of cells with jasplakinolide, which is a cell-
permeable analog of phalloidin (23).
Discussion
We have used a peptide (pHLIP) that predominantly inserts
across a cell membrane at low pH (7.0) but not at normal
physiological pH. By translocating a molecule into a cell and
releasing it in the cytoplasm, pHLIP functions, in effect, as a
nanosyringe. The peptide does not exhibit any elements of
helical secondary structure in solution or on the cell membrane
at neutral pH; however, it becomes rigid (as a syringe needle)
when it inserts into a lipid bilayer, and it forms a transmembrane
helix and injects molecules into cells. We demonstrated that
pHLIP inserts across the membrane at low pH and can release
disulfide-linked membrane-impermeable molecules, such as
PNA and phalloidin, inside cells. Based on all our data, we
conclude that the pathway of peptide entry into the membrane
and the translocation of molecules into cells are not mediated by
endocytosis, by interactions with cell receptors, or by formation
of pores in cell membranes; rather, it is the formation of a helix
across the lipid bilayer, triggered by the increase of the peptide
hydrophobicity due to the protonation of Asp residues induced
by low pH. This insertion is consistent with the recent scale of
Hessa et al. (24), where the membrane insertion scale is shown
to be more favorable for the protonated form of Asp. Our
estimation of the free energy of insertion showed that the
transbilayer configuration of the protonated pHLIP peptide is
favored compared with the most stable peripheral configuration
by at least 3 kcalmol (ref. 11 and Y.K.R. and D.M.E., unpub-
lished results). We hypothesize that this energy might be used to
bias the translocation of cargo molecules by pHLIP through the
cell membrane. ODN, with high negative charge, might have too
high a barrier for its translocation across a membrane on the time
scale of our experiments. In contrast, PNA has a charge neutral
backbone [N-(2-aminoethyl)glycine units] and thus a lower
energy barrier, which makes it suitable for pHLIP translocation.
The size range and polarity of cargo molecules that pHLIP can
translocate through the membrane remain to be studied.
pHLIP offers a new technology for the fast and efficient
delivery of drugs, imaging probes, or cell and gene regulation
agents into living cells. The method allows translocation of
certain cell-impermeable molecules into a cell or the attachment
of a variety of functional moieties and particles to the cell surface
at low pH. The pH-selective delivery properties of pHLIP may
provide a new approach for diagnosis and treatment of diseases
with naturally occurring (or artificially created) low-pH extra-
cellular environments, such as tumors, infarcts, stroke-aff licted
tissue, atherosclerotic lesions, sites of inflammation or infection,
or damaged tissue resulting from trauma (25–28).
Fig. 5. Cytofluorometry of HeLa cells. (a and b) The untreated cells (a) and
cells treated with Ph–TRITC (b) at pH 6.5 and 37°C are shown. (c–e) Cells treated
(for 1 h) with 6M pHLIP–S–S–Ph–TRITC at pH 7.4 and 37°C (c), pH 6.5 and 37°C
(d), and pH 6.5 and 4°C (e) are shown.
Fig. 6. Cell phenotypes induced by phalodin transport. (a) Phase-contrast
images of HeLa cells incubated (for 1 h) with pHLIP–S–S–Ph–TRITC (1M) at pH
6.5 and 7.4 followed by washing with PBS (pH 7.4) before (Left) and 5 min after
adding of the dissociation solution (Right). Cells treated with the peptide–
phalloidin at low pH remained unchanged, consistent with stabilization of the
cytoskeleton by Ph–TRITC delivered by the pHLIP. (b) Fluorescence images of
nuclei stained with DAPI (0.5M) and corresponding phase-contrast images of
the multinucleated HeLa cells are presented. Multinucleation was observed at
48 h after treatment of cells with of pHLIP–S–S–Ph–TRITC (1 M) at pH 6.5
for 1 h.


















Synthesis of Peptide and Peptide–Cargo Constructs. pHLIP was
prepared by solid-phase peptide synthesis by using standard
9-fluorenylmethyloxycarbonyl chemistry and purified by re-
verse-phase chromatography (on a C18 column) at the W.M.
Keck Foundation Biotechnology Resource Laboratory at Yale
University. In a typical preparation of the soluble form of the
peptide, the lyophilized powder was dissolved in a solution
containing 6 M urea and was transferred to working buffer by
using a G-10 size-exclusion spin column. The concentration of
the peptide was determined by absorbance (280  13,940
M1cm1) and was confirmed by quantitative amino acid anal-
ysis. The peptide was labeled at its single C-terminal cysteine
residue with dansyl, Texas red, or rhodamine by incubation with
didansyl (Sigma), Texas red maleimide (Molecular Probes), or
tetramethylrhodamine maleimide (Molecular Probes) in 10 mM
TrisHCl20 mMNaCl6 M urea, pH 8.0, in dark at 4°C for 24 h.
The conjugated peptides were purified on a G-10 size-exclusion
column and transferred to PBS buffer (pH 7.4). The concentra-
tion of labeled peptide was determined by absorbance (dansyl,
340  4,300 M1cm1; Texas red, 582  112,000 M1cm1;
rhodamine, 542  65,000 M1cm1).
pHLIP was conjugated to Ph–TRITC (Sigma) by using
bifunctional photocrosslinkers: S-[2-(4-azidosalicylamido)ethyl-
thio]-2-thiopyridine (Molecular Probes) or benzophenone-4-
iodoacetamide (Molecular Probes). The first crosslinker {S-[2-
(4-azidosalicylamido)ethylthio]-2-thiopyridine} makes an S–S
bond with the C terminus of the peptide and binds to Ph–TRITC
under UV irradiation (pHLIP–S–S–Ph–TRITC). The second
crosslinker was used for the synthesis of the noncleavable
construct (pHLIP–Ph–TRITC). pHLIP was incubated with the
crosslinker in PBS in the dark at 4°C for 24 h. Excess crosslinker
was removed by using a G-10 size-exclusion spin column. A 5
molar excess of Ph–TRITC was added to the pHLIP crosslinker
and illuminated at 340 nm for 30 min. The unreacted Ph–TRITC
was removed by using a G-10 size-exclusion column. The con-
centration of rhodamine was determined by absorption at 542
nm (542  65,000 M1cm1). Separately, the Ph–TRITC was
conjugated to S-[2-(4-azidosalicylamido)ethylthio]-2-thiopyri-
dine without peptide. The conjugation of Ph–TRITC to
crosslinker or pHLIP did not affect its ability to bind to F-actin
(data not shown).
TAMRA-o-o-CATAGTATAAGT-o-Cys-NH2–PNA with
Cys and fluorescent dye, TAMRA, was synthesized by Applied
Biosystems. This PNA targets MDM2 mRNA (29). PNA–
TAMRA was incubated with a 4 molar excess of pHLIP for
24 h in PBS (pH 7.4) at 4°C. pHLIP–S–S–PNA–TAMRA
construct was purified on G-10 column. The concentration was
determined by measuring absorption at 546 nm (542  65,000
M1cm1).
FITC-(5-GTTCTCCCAGCGTGCGCCAT-3)-SH was syn-
thesized by Eurogentec. FITC–ODN targets Bcl-2 protoonco-
gene mRNA (30). It was conjugated to pHLIP by the same
method as described above for PNA conjugation. Concentration
of pHLIP–S–S–ODN–FITC was measured by the absorption at
492 nm (492  56,000 M1cm1).
Liposome Preparation. Large unilamellar vesicles were prepared
by sonication. The POPC (Avanti Polar Lipids) phospholipid was
dissolved in chloroform. After removal of the solvent using a
rotary evaporator, the phospholipid film was dried overnight and
then rehydrated in 10 mM TrisHCl20 mM NaCl, pH 8.0, and
vortexed. The suspension was sonicated by using a Branson
titanium tip ultrasonicator until the solution became transpar-
ent. The liposomes distribution was evaluated by dynamic light
scattering. The vesicles radius was 72.6  4.6 nm (polydispersity
was 13.6  6.7%). To prepare liposomes with dithionite inside
them, the phospholipid film was rehydrated in 1 M Tris buffer
(pH 8.0) containing 1 M dithionite. Untrapped dithionite was
removed from the solution of liposomes by using a dialysis
cassette with 10-kDa cutoff pores. Dialysis was performed
against 10mMTrisHCl20mMNaCl, pH 8.0, for 4 h with hourly
solution changes.
Detection of Peptide Topology. External addition of dithionite
(Na2S2O4) to large unilamellar vesicles chemically quenches the
NBD fluorescence in the outer leaflets of the bilayers. The
peptide was labeled at N terminus with NBD by incubation with
NBD-Cl (Molecular Probes) in 10 mM TrisHCl20 mM NaCl,
pH 7.0, in dark at 4°C for 24 h (the peptide:NBD ratio was 1:20).
The conjugated peptide was purified in a G-10 size-exclusion
column. The concentration of labeled peptide was determined by
absorbance (480  25,000 M1cm1; 336  9,800 M1cm1).
The labeled peptide was incubated with liposomes at neutral pH,
and insertion was triggered by the reducing of pH to 4.0. The
fluorescence spectra of the peptide labeled with NBD in solution
and inserted into lipid bilayer were recorded on a SLM8000
spectrofluorometer. Changes in the fluorescence signal of NBD
were monitored at 530 nm (excited at 470 nm) after addition of
the dithionite and disruption of the liposomes by Triton X-100.
In other experiments, liposomes containing dithionite were
added to the labeled peptide in solution at pH 8.0, the pH was
then decreased to 4.0, Triton X-100 was added to disrupt the
liposomes, and more dithionite was added for the complete
quenching of the NBD fluorescence.
Cell Lines. Both human and mouse cancer cell lines were used in
our study. HeLa cells were provided by the Cancer Center of
Yale University Medical School. Prostate, TRAMP-C1 (CRL-
2730), and breast adenocarcinoma (CRL-2116) were from the
American Type Culture Collection. Cells were cultured in
DMEM supplemented with 10% FBS, 100 unitsml penicillin,
0.1 mgml streptomycin, and 2 mM glutamine in a humidified
atmosphere of 5% CO2 and 95% air at 37°C.
Cytotoxicity Assay. Cytotoxicity was tested by using a standard
colorimetric assay according to an established protocol provided
by Promega. HeLa cells were loaded in the wells of 96-well plates
(20,000 cells per well) and incubated for 24 h in DMEM
supplemented with 10% FBS, 100 unitsml penicillin, 0.1 mgml
streptomycin, and 2 mM glutamine in a humidified atmosphere
of 5% CO2 and 95% air at 37°C. The growth medium was then
replaced with the same medium but containing 1% of FBS and
increasing amounts of pHLIP (0.5, 1, 2, 4, 8, and 16 M). After
24 h of incubation, the solution was replaced with DMEM and
a colorimetric reagent (CellTiter 96 AQueous One Solution
Assay) was added for 1 h followed by measuring absorbance at
490 nm in the plate reader. All samples were prepared in
triplicate.
Membrane Leakage Assay.HeLa cells were loaded in 96-well plates
(2,000 cells per well) and incubated for 24 h in DMEM supple-
mented with 10% FBS, 100 unitsml penicillin, 0.1 mgml
streptomycin, and 2 mM glutamine in a humidified atmosphere
of 5% CO2 and 95% air at 37°C. The growth medium was then
replaced with PBS buffer containing 1 mM CaCl2 and 1 mM
MgCl2 at pH 7.4 or 6.5 and increasing amounts of the peptide
(0.5, 2, 5, and 10 M). After 1 h, 2 M Ph–TRITC and 0.5 M
SYTOX–Orange (Molecular Probes) were added for 10 min in
the presence of peptide and then washed with PBS buffer (pH
7.4). The rhodamine fluorescence was measured at 580 nm with
excitation at 544 nm by plate reader. The cell membrane was
subsequently disrupted by adding 0.5% Triton X-100 and a new
portion of the 2 M Ph–TRITC and 0.5 M SYTOX–Orange
followed by washing with PBS. The fluorescence signal was
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detected before and after washing, respectively. All samples were
done in triplicate.
FluorescenceMicroscopy.For the fluorescencemicroscopy studies,
the cells were grown in 35-mm dishes with 10-mm glass-bottom
windows coated with collagen. Cells were washed with PBS
buffer containing 1 mMCaCl2 and 1 mMMgCl2 with pH 5.5, 6.5,
7.0, or 7.4 and then incubated in PBS at the experimental pH in
the absence or presence of varied concentrations (0.1–7 M) of
the pHLIP–S–S–dansyl, pHLIP–dye (Texas red or rhodamine),
pHLIP–S–S–Ph–TRITC, pHLIP–Ph–TRITC, pHLIP–S–S–
PNA–TAMRA, or pHLIP–S–S–ODN–FITC constructs. The
medium pH was measured before and after incubation. The time
of incubation was varied from 15 to 60 min. The cancer cells can
acidify the medium (PBS buffer) in a few minutes if the
incubation volume is small, creating the problem of maintaining
constant pH 7.4 in the PBS incubation buffer. We therefore
preferred to use a low density of cells in the chamber, a larger
volume, and a higher phosphate concentration (up to 50 mM
instead of the standard 10 mM PBS), and we routinely checked
the pH before and after the experiments. The incubation was
followed by the replacement of the PBS buffer with Leibovitz’s
L-15 phenol free medium (supplemented with 5% FBS, 100
unitsml penicillin, 0.1 mgml streptomycin, and 2 mM glu-
tamine) at the experimental pH for 1 h and then (if not indicated
otherwise) at pH 7.4. To monitor multinucleated cells we used
nuclear-staining dye DAPI (Sigma–Aldrich). HeLa cells were
treated with pHLIP–S–S–Ph–TRITC in PBS at pH 6.5 for 1 h
followed by changing solution with DMEM supplemented with
10% FBS, 100 unitsml penicillin, 0.1 mgml streptomycin, and
2 mM glutamine in a humidified atmosphere of 5% CO2 and
95% air at 37°C. After 48 h 0.5 M DAPI was added followed
by washing. Fluorescent images were taken by using an inverted
epifluorescence microscope (Olympus IX71). Some images of
cells stained with pHLIP–phalloidin–TRITC noncleavable con-
struct were taken on the Zeiss Axioplan 2 light microscope with
Zeiss LSM 5 PASCAL laser scanning module with excitation at
543 nm of HeNe laser. The images of cells stained with dansyl
were taken on a Bio-Rad MRC-1024 two-photon confocal
microscope with excitation at 740 nm. Each time we performed
fluorescence microscopy experiments and observed the trans-
location of cargo by pHLIP, we verified that labeled cells were
alive by using the dead cell marker SYTOX–Green (Molecular
Probes).
Flow Cytometry. Analytic f low cytometric measurements were
performed by using a FACS instrument. Ten thousand cells were
analyzed in each sample. The cells were suspended in PBS at pH
6.5 or 7.4 in presence and absence of (6 M) pHLIP–S–S–Ph–
TRITC at 4°C or 37°C for 1 h. Then they were washed twice with
PBS buffer (pH 7.4), resuspended in PBS (pH 7.4), and analyzed
on the FACS instrument.
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